• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Products
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • Investor Information
    • News & Articles
    • Careers
  • About Us
    • Our Values
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Contact

Webinar: Overcoming the Delivery Challenge for Nucleic Acid Drugs

August 27, 2021 By Exopharm Ltd

On August 26 we presented our Science Webinar with Dr Jennifer King and Dr Anna Cifuentes-Rius about overcoming the delivery challenge for nucleic acid drugs. Deputy CEO & Chief Commercial Officer, Dr Chris Baldwin hosted the event and there was Q&A at the end of the presentations. After the technical and scientific questions were answered, Dr Chris Baldwin and CEO Dr Ian Dixon were on hand to address business-related questions relating to Exopharm.

We would like to thank our presenters Dr King and Dr Cifuentes-Rius for their engaging presentations and insights into nucleic acids and drug delivery and to our audience members for asking some interesting questions and engaging in the live webinar. We hope you enjoy the replay. To access the presentation slides, click here.

Watch the Replay on Vimeo

 

Topics

RNA Medicines and Delivery: The Importance for the Future of Medicine
Dr Jennifer King
King BioConsulting

Nucleic acid medicines are making the news and receiving marketing approvals in major jurisdictions. Dr Jennifer King discussed how pharmaceutical therapies have evolved from small molecule drugs to these nucleic acid-based medicines, and the promise that this emerging class of therapies holds for treating human disease.

Delivery by LNPs and Exosomes: When They Are Useful and Why

Dr Anna Cifuentes-Rius
Monash University

Despite the promise of nucleic acid therapies, their delivery within the body remains a major challenge. Dr Anna Cifuentes Rius discussed how the industry is working to use synthetic lipid-based nanoparticles to improve delivery, as well as the areas where exosomes, i.e. nanoparticles of biological origin, can overcome the limitations of their synthetic counterparts.

About the Presenters

Dr Jennifer King

Jennifer King, a Principal at King BioConsulting, has over 20 years of operating experience in the biopharmaceutical industry.  King BioConsulting provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications.  From 2015 to 2019 Jenn served at Intellia Therapeutics, a CRISPR Cas9 genome editing start-up, completing her tenure as Senior Vice President for Business Development.

Prior to her joining Intellia in 2015, Jenn held the position of Senior Director of Business Development at Shire Plc, (now Takeda) where she was responsible for the sourcing, initial evaluation and negotiation of licensing and acquisition opportunities within the company’s corporate development group. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®.

Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.  In addition to a passion for biology and the biopharmaceutical industry, Jenn is an avid sailor and world traveller, and just completed her 100th scuba dive.

Dr Anna Cifuentes-Rius
Dr Anna Cifuentes-Rius is an NHMRC Early Career Fellow at Monash University. She has established an international and multidisciplinary research program with a focus on both fundamental and applied nanomedicine. Her research aims to understand the interactions between drug delivery systems and biological tissues with the ultimate goal of improving current therapy and diagnostic approaches. She has been trained at the Massachusetts Institute of Technology, University of Queensland, and University of South Australia. In 2013, she completed her PhD at Institut Quimic de Sarria (Ramon Llull University, Barcelona). Among her passions are empowering young researchers and promoting equitable leadership in science.

 

Filed Under: News, Talks & Webinars

Footer

Resources

  • ASX Announcements
  • Investor Information
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2022 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT